Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in COVID-19
NCT05038449Unknown
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of colchicine in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Recovery rate of clinical symptoms and virus negative conversion rate (RT-PCR) at Day 7. Status: unknown.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05038449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038449.